Jade Biosciences, Inc. (JBIO) Revenue History
Annual and quarterly revenue from 2020 to present
JBIO Revenue Over Time (2020–2025)
JBIO Revenue Growth History
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
| Q1 2024 | $0 | — |
JBIO Revenue Analysis (2020–2025)
Current Revenue & Growth
As of June 12, 2026, Jade Biosciences, Inc. (JBIO) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
JBIO's historical revenue data shows various trends over time.
Peer Comparison
Compared to Healthcare sector peers — including KRYS (+25.1% YoY), RCUS (+67.4% YoY), and ARQT (+95.3% YoY). Compare JBIO vs KRYS →
JBIO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 JBIOCurrent | $0 | - | - | - | |
 KRYS | $389M | +25.1% | - | 41.5% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 ARQT | $376M | +95.3% | - | -3.3% | |
 DAWN | $158M | +20.6% | - | -80.8% |
JBIO Historical Revenue Data (2020–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-113,542,000 | - |
| 2024 | $0 | - | $-282,000 | - | $-74,596,000 | - |
| 2023 | $0 | - | $-96,000 | - | $-81,409,000 | - |
| 2022 | $0 | - | $-68,000 | - | $-53,237,000 | - |
| 2021 | $0 | - | $-15,000 | - | $-23,022,000 | - |
| 2020 | $0 | - | $-1,000 | - | $-8,889,000 | - |
What if you invested $1,000 in JBIO back in 2020?
Total return with dividends reinvested · 6+ years of data
Calculate ReturnsHow much would $100/month in JBIO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs JBIO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationJBIO vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowJBIO — Frequently Asked Questions
Quick answers to the most common questions about buying JBIO stock.
Is JBIO's revenue growth accelerating or slowing?
JBIO TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is JBIO's revenue history from 2020 to 2026?
Jade Biosciences, Inc. (JBIO) revenue history spans 2020 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is JBIO's long-term revenue growth rate (CAGR)?
Jade Biosciences, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for JBIO.
Why does JBIO's quarterly revenue fluctuate?
JBIO quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Jade Biosciences, Inc.'s revenue data from 2020 to 2026 shows full historical quarterly detail on this page.
How is JBIO's revenue distributed by segment?
JBIO reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does JBIO's revenue compare to industry peers?
Jade Biosciences, Inc. (JBIO) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.